It was reported on Tuesday, that DxTerity Diagnostics Inc, a molecular information and diagnostics company, has named Brett Swansiger as its new chief commercialization officer (CCO).
Swansiger will be responsible for identifying, developing, and negotiating strategic business collaborations with life-science organizations and establishing government and commercial payer contracts for DxTerity testing. Swansiger has experience managing care contracting in the molecular diagnostics and pharmaceutical industries. Prior to joining DxTerity, he held commercial leadership positions at MDxHealth Inc including VP of Managed Care and Payer Strategy, SVP International Business Development & European Sales, and SVP of US Sales & Integrated Healthcare Systems.
Swasniger was earlier vice president of Managed Care and Asia Market Access at Agendia Inc and held a number of commercial leadership roles at Prometheus Laboratories Inc.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer